Imatinib

In the US, Imatinib (imatinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome, Myelodysplastic Diseases, Myeloproliferative Disorders and Systemic Mastocytosis.

US matches:

UK matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XE01

CAS registry number (Chemical Abstracts Service)

0152459-95-5

Chemical Formula

C29-H31-N7-O

Molecular Weight

493

Therapeutic Category

Antineoplastic agent: Tyrosine kinase inhibitor

Chemical Names

alpha-(4-methyl-1-piperazinyl)-3'-[[4-(3-pyridyl)-2-pyrimidinyl]amino]-p-tolu-p-toluidide- (WHO)

Benzamide, 4-((4-methyl)-1-piperazinyl)methyl)-N-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)phenyl)-

Foreign Names

  • Imatinibum (Latin)
  • Imatinib (German)
  • Imatinib (French)
  • Imatinib (Spanish)

Generic Names

Brand Names

  • Celonib
    Celon, India
  • Glivec
    Novartis, Greece; Novartis, Tunisia; Novartis, Turkey
  • Mesylonib
    Miracalus, India
  • Mitinab
    Glenmark, India
  • Shantinib
    Shantha, India
  • Enliven
    Orion, Bangladesh
  • Gleevec
    Novartis, Canada; Novartis, United States; Novartis, South Africa
  • Glivec
    Novartis, Argentina; Novartis, Australia; Novartis, Bosnia & Herzegowina; Novartis, Bangladesh; Novartis, Belgium; Novartis, Bulgaria; Novartis, Bahrain; Novartis, Brazil; Novartis, Switzerland; Novartis, Chile; Novartis, China; Novartis, Czech Republic; Novartis, Germany; Novartis, Denmark; Novartis, Ecuador; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Georgia; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Japan; Novartis, South Korea; Novartis, Lithuania; Novartis, Mexico; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Portugal; Novartis, Romania; Novartis, Serbia; Novartis, Sweden; Novartis, Singapore; Novartis, Slovenia; Novartis, Slovakia; Novartis, Thailand; Novartis, Taiwan; Novartis, Venezuela; Novartis, Vietnam; Novartis Biosciences, Peru; Novartis Europharm, Austria; Novartis Europharm, Poland; Novartis Europharm Limited, Latvia; Novartis Farma, Italy; Novartis Farmaceutica, Spain; Novartis Healthcare, Philippines
  • Imatib
    Grey Inversiones, Peru
  • Plivatinib
    Pliva, Croatia (Hrvatska)

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide
(web4)